Breast Cancer CRO & Clinical Trial Services
Ergomed provides specialized oncology CRO services with a focus on breast cancer. Our site management network ensures rapid patient recruitment for complex protocols. We have extensive experience with biomarkers, immuno-oncology, and antibody-drug conjugates (ADCs), ensuring high-quality data and patient safety throughout your study.
Driving Innovation in Breast Cancer Research
Our global infrastructure and oncology-trained teams support clinical programs across North America, Europe, and emerging markets, while maintaining focus on patient safety, regulatory compliance, and timely delivery.
Whether you’re developing treatments for HER2-positive, TNBC, or hormone receptor-positive breast cancer, Ergomed offers the strategic CRO partnership you need to succeed.
Our Breast Cancer Trial Expertise
We tailor every program to the specific needs of your molecule, mechanism, and population—bringing agility and expertise to every step.
- Experience in ADC trials and novel biologics, including dose-finding and expansion studies
- Proven success with targeted therapies, immuno-oncology agents, and combination regimens
- Expertise across Phase I–III trials, including adaptive and basket trial designs
- Full-service delivery including medical monitoring, regulatory strategy, and data quality oversight
- Strong engagement with KOLs and academic research centers in oncology
- Patient-centric approach to improve recruitment, retention, and compliance
Anti-Body Conjugates | A new step forward for Breast Cancer Patients
This article provides an in-depth look at the evolving role of ADCs, covering significant trial results, quality-of-life benefits, and the future potential of “smart chemotherapy” for advanced breast cancer therapies.
Transforming First-in-Human Oncology Trials: A Strategic Guide
Ergomed empowers biopharma sponsors to design and deliver first-in-human oncology trials with confidence—combining regulatory expertise, patient-centric strategies, and operational excellence to accelerate early-phase development and reduce risk.
Let’s Advance Breast Cancer Research – Together
Partner with a CRO that combines global scale with deep, focused oncology expertise. At Ergomed, we understand that every breast cancer study brings unique challenges, from patient recruitment and biomarker-driven trial design to navigating evolving regulatory pathways.